Cytokinetics Inc To Discuss Omecamtiv Mecarbil Regulatory Update Call Transcript
Good morning, and welcome, ladies and gentlemen, to Cytokinetics conference call. At this time, I'd like to inform you that this call is being recorded. (Operator Instructions)
I will now turn the call over to Diane Weiser, Senior Vice President of Corporate Communications and Investor Relations. Please go ahead.
Good morning, and thanks for joining us on the call today to discuss the regulatory update related to omecamtiv mecarbil. On the call with me today are Robert Blum, President and Chief Executive Officer, who will make opening remarks; and Fady Malik, EVP of Research and Development; Andrew Callos, EVP and Chief Commercial Officer; and Ching Jaw, SVP and Chief Financial Officer, who will participate in our Q&A.
Please note that portions of the following discussion, including our responses to questions, contain statements that relate to future events and performance rather than historical facts and constitute forward-looking statements. Our actual
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |